First-Line Treatment with Irinotecan and Raltitrexed in Metastatic Colorectal Cancer
| Autor: | Carles Bosch, Isabel Busquier, Cristina Llorca, Salvador Garcera, Miquel Balcells, J. M. Campos, José María Vicent, A. Galan, Jorge Aparicio, I. Maestu, Pedro López-Tendero |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty biology business.industry Colorectal cancer Topoisomerase Phases of clinical research General Medicine medicine.disease Thymidylate synthase digestive system diseases Surgery Metastasis Irinotecan Clinical trial Internal medicine biology.protein Medicine business neoplasms Raltitrexed medicine.drug |
| Zdroj: | Oncology. 68:58-63 |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000084821 |
| Popis: | Objectives: The combination of irinotecan and raltitrexed is safe and active in 5-fluorouracil-refractory, metastatic colorectal cancer (CRC), with the advantage of its convenient three-weekly schedule. The aim of this multicenter phase II study was to assess its efficacy and toxicity in first-line treatment. Methods: Between May 2000 and March 2001, 62 previously untreated patients received irinotecan (350 mg/m2) plus raltitrexed (3 mg/m2), with courses repeated every 21 days. Objective response was assessed every three courses, and treatment maintained until tumor progression or unacceptable toxicity. Results: A total of 331 cycles were administered, with a median of five cycles per patient (range, 1–16). Seventeen patients achieved a partial response and 2 a complete response, for an overall intention-to-treat response rate of 30% (95% confidence interval, 18–44%). The incidence of grade 3–4 toxicity per patient was diarrhea (27%), emesis (13%), anemia (12%), neutropenia (9%), and asthenia (7%). Three patients (5%) died from treatment-related adverse events (diarrhea plus neutropenia). The median potential follow-up is now 37 months. Median survival was 12.2 months, and median time to progression was 6.3 months. Conclusions: The combination of irinotecan plus raltitrexed is an easy comfortable schedule for patients with metastatic CRC, but both efficacy and toxicity results seem suboptimal for first-line treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|